Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios

Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan

“…A previously developed lifetime Markov cohort model with a 1-year cycle simulating the natural history of oncogenic HPV in cervical cancer (normal, HPV infection, cervical intraepithelial neoplasia [CIN], cervical cancer, cervical cancer deaths, other deaths) and the effect of screening and vaccination was adapted to reflect the Taiwanese settings [20,23,24]. An additional component to the initial model was appended by Demarteau and Standaert [25] to account for the low-risk HPV infections (including HPV types 6 and 11) that may result in CIN1 and/or GW.…”

“…In a study by Suárez et al [20], the cost-effectiveness of HPV vaccination versus screening alone was evaluated for five countries or regions, including Taiwan. Suarez et al estimated the incremental cost-effectiveness of HPV vaccination, with a bivalent vaccine, versus no vaccination at new Taiwan dollars (NT $) 278,665 per quality-adjusted life-year (QALY) gained (ϭUS $8,700) for Taiwan at a vaccine price of NT $4,000 per dose.…”

Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore

“…Although the phenomenon of waning is uncertain, (29) it is included in many modelling studies in which the estimated benefit of vaccination is reduced as a result.…”

“…(4) Recent studies have suggested that AS04-HPV-16/18v also provides moderate cross-protection against persistent infection by HPV-6 and HPV-11. (21)(22)(23)(24) The cost-effectiveness of both AS04-HPV-16/18v and 4vHPV has been evaluated in a number of countries in order to establish the value of introducing nationwide immunisation programmes, (25)(26)(27)(28)(29) in accordance with the World Health Organization's (WHO) recommendation to first establish the cost-effectiveness of a new vaccine in the country before introduction. (30) While the effectiveness and cost-effectiveness of the three-dose vaccine regimens have been evaluated for Singapore, (31,32) there are no such cost-effectiveness studies on the two-dose vaccine regimens to our knowledge.…”

A human papillomavirus public vaccination program in Taiwan: The Kinmen County experience

“…9,10 Vaccine uptake is crucial to the success of a publicly funded HPV vaccination program. Several factors can affect the rate of public acceptance.…”